Savara (SVRA) Revenue (2013 - 2020)

Savara's (SVRA) quarterly Revenue came in at $1000.0 in Q4 2020, down 99.61% on a QoQ basis from $256000.0 in Q3 2020.

Savara (SVRA) Revenue (2013 - 2020) Analysis & Trends

Savara (SVRA) has 5 years of Revenue data on file, last reported at $1000.0 in Q4 2020.

On a quarterly basis, Revenue changed N/A year-over-year to $1000.0 in Q4 2020; TTM through Mar 2022 was $1000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $257000.0, changed N/A from the prior year.
Revenue for Q4 2020 stood at $1000.0, down from $256000.0 in the prior quarter.
Over the last five years, Revenue for SVRA reached as high as $400000.0 in Q4 2016 and fell as low as -$94000.0 in Q2 2017.
Historically, Revenue has averaged $117000.0 across 3 years, with a median of $69500.0 in 2016.
On a YoY basis, Revenue climbed as much as 640.74% in 2016 and fell as far as 640.74% in 2016.
Year by year, Revenue stood at $400000.0 in 2016, then tumbled by 123.5% to -$94000.0 in 2017, then jumped by 101.06% to $1000.0 in 2020.
Per Business Quant data, the three most recent Revenue figures were $1000.0 in Q4 2020, $256000.0 in Q3 2020, and -$94000.0 in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	1.51 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	2.99 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	3.61 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	1.30 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Savara	1.39 Bn	1.39 Bn	-	-

Download Data